FDA hands AbelZeta dual designations for its lymphoma CAR-T

AbelZeta snagged two FDA designations for its lead CAR-T candidate on Nov. 10. The agency granted both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track status to Prizloncabtagene Autoleucel, or Prizlon-cel, a bispecific CAR-T aimed at patients with relapsed or refractory large B-cell lymphoma. The designations sit under the company's Investigational New Drug application, STN 32908.

Prizlon-cel, also known as A-CAR039, targets both CD20 and CD19 — a two-pronged approach to hunting down the cancer cells that drive LBCL. AbelZeta, based in Rockville, Maryland, calls itself a cell therapy company focused on oncology and inflammatory and immunological diseases. The dual designations back its continued U.S. development push in r/r LBCL.

The company's plan splits into two tracks. ABZT-121, a Phase 2 study registered as NCT07875413, tests Prizlon-cel in patients who already went through an FDA-approved, commercially available CAR T-cell therapy. AbelZeta says results there could potentially support an accelerated-approval pathway, contingent on the clinical data and future talks with the FDA.

The second track, ABZT-131, is a randomized clinical study of Prizlon-cel in second-line treatment of r/r LBCL. That one is designed to test the therapy earlier in the treatment course and suss out where it fits alongside established CAR T-cell treatments. Together, the two trials are meant to cover multiple r/r LBCL treatment settings.

What do the stamps actually buy? RMAT opens the door to intensive FDA interaction on clinical development, including talks meant to smooth the path toward a possible approval. Fast Track is built to speed development and review for serious conditions with unmet need, offering more frequent FDA meetings and rolling review of sections of a future Biologics License Application if the requirements are met.